Price Target: 7,00 US$, a Upside Potential 586 %, from where the stock is currently trading.
*
On the ratings front, Biolinerx has been the subject of a number of recent research reports. In a report issued on September 8, Roth Capital analyst Joseph Pantginis maintained a Buy rating on BLRX, with a price target of $7.00, which represents a potential upside of 586% from where the stock is currently trading.
*
Pl.s read the News at the Smarter analyst, at the link as follows.
*
http://www.smarteranalyst.com/2016/09/22/company-update-nasd…